ASH 2013 Annual Meeting

Atlanta, GA—A chemotherapy-free regimen for patients with acute promyelocytic leukemia (APL) achieved a 2-year survival of almost 100% with less toxicity compared with cytotoxic regimens, according to a study reported at the 2012 American Society of Hematology (ASH) meeting.
Read Article

Atlanta, GA—The promise of regenerative medicine is exemplified by the regeneration of corneal epithelium from human limbal stem-cell culture.
Read Article

Atlanta, GA—Targeting Bruton’s tyrosine kinase (BTK) in patients with chronic lymphocytic leukemia (CLL) resulted in high response rates, without severe toxicity, according to the results of 2 studies that were presented at the 2012 American Society of Hematology meeting.
Read Article

Atlanta, GA—The new oral tyrosine kinase inhibitor (TKI) ponatinib (Iclusig) has significant activity and is well tolerated in patients with highly pretreated chronic myeloid leukemia (CML) or with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) who otherwise lack therapeutic options.
Read Article

Patients with multiple myeloma receiving bortezomib (Velcade) in the pivotal VISTA trial lived more than 1 year longer than those in the control group, according to the final, 5-year analysis of the study presented at the 2011American Society of Hematology annual meeting.
Read Article

Page 2 of 2